ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Consumer Discretionary / NUTX / financials
LQDT (74) RDWR (58) RSKD (55) AHG (34) ⌘ Pro Terminal β†’

Nutex Health Inc. (NUTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$200.15 -4.74% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $198.92

Nutex Health Inc. (NUTX) earns a Roarable Rating of A (Strong Buy) with 86/100 RQD Confidence. High-quality cash engine (51% profit margin, 85% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

πŸ“Š Historical Track Record: Scores of 86/100 (A) historically ranked in the Top 5% of excess returns over the next 90 days (+9.2% avg 90D alpha vs SPY β€’ 73.2% hit rate) β†’
ROARABLE A β€’ STRONG BUY Cap $1.44B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NUTX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is NUTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Nutex Health Inc. (NASDAQ: NUTX) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 86/100 at a spot price of $200.15 (-4.74% 1D, market cap $1.44B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 19/20. Across 1011 tracked Consumer Discretionary issuers, NUTX ranks #6 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does NUTX compare to LQDT and RDWR in the Consumer Discretionary sector?
β–Ό

Within the Consumer Discretionary sector (Business Services), NUTX carries a Roarable A (86/100 RQD), trailing P/E of 20.3x, gross margin of 50.8%, and ROIC of 85.0%. By comparison, LQDT (Liquidity Services Inc.) holds a B grade (74/100 RQD, P/E 50.5x, ROIC 12.9%, cap $1.42B) and RDWR (Radware Ltd.) posts a D+ grade (58/100 RQD, P/E 76.5x, ROIC 3.7%, cap $1.55B). Among the 5-stock peer group, NUTX leads on earnings multiple (20.3x) while NUTX leads on capital efficiency (85.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NUTX?
β–Ό

Per NUTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001479681), Nutex Health Inc. generated $875.3M in revenue (+82.4% YoY), $70.8M in net income, and $245.6M in free cash flow against $918.5M in total assets and $29.2M in total debt. Key quantitative strengths: Strong cash generator (51% profit margin)β€”profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $198.93 (-0.61%)🧬 Cannibal Buyback (-3.20% YoY Shares)βš™οΈ Cash Engine: 19/20 (A+) β€’ 28.1% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 86/100 (A) historically ranked in the Top 5% of excess returns over the next 90 days (+9.2% avg 90D alpha vs SPY β€’ 73.2% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSTRONG BUY β€’ A
025507510086
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A Β· Rk A-
Cash (19)Whales (14)SEC (16)Macro (18)CEO (19)
Each axis scored 0–20
12M PRICE TARGET CONE+12.6% Base Target
$266 Bull$225 Base$164 Bear
πŸ“¬ FREE NUTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for NUTX)Realized 20D OHLCV Swing Band: Β±11.2%
Deterministic 5-Pillar Attribution (86/100 Composite)
πŸ” WHY NUTX SCORES 86/100 (A) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+19/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 28.1% FCF Margin ($245.6M FCF) & 50.8% Gross Margin

β–² #2 Bullish Driver: Insider Conviction & Share Dilution+19/20 pts (22% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy β€’ Cannibal Buyback (-3.20% YoY Shares)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning14/20 pts (-6 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-6 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
94
Grade A+$206.15-7.2% Next Q
Q2 (-2Q)
91
Grade A+$191.25+9.3% Next Q
Q3 (-1Q)
89
Grade A$209.01-4.2% Next Q
Current
86
Grade A$200.15+9.2% Hist 90D Ξ±
Trajectory: A+ (94) β†’ A (86)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the NUTX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 86/100 (A) score, NUTX faces multiple-compression risk if 20.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) β€” any gross margin slip below 48.3% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($203.73) or 200D SMA ($150.67) invalidates the momentum regime and cuts Target Base ($225.37) toward Bear Floor ($164.12).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NUTXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œNUTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 86%NO 14%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How NUTX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$245.6M (28.1% FCF Margin)
Revenue$875.3MGross Profit $444.3M (50.8%)Cost of Sales $431.0MOp Profit $275.6M (31.5%)OpEx (R&D/SG&A) $168.7MNet Profit$70.8M (8.1%)Tax/Other $204.8M

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $247.6M
FY24
Rev $479.9M
FY25
Rev $875.3M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$875.3M50.8%31.5%$70.8M$245.6M95%
FY 2024$479.9M40.9%27.2%$52.1M$20.8M90.4%
FY 2023$247.6M50.8%-12.8%-$45.8M$1.3M85%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NUTX)

  • βœ“Walkthrough of NUTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
NUTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +36.00%β–² ASCENDING CHANNEL
2026-11-02O $212.6H $212.6L $200.2C $200.2VOL 79.6K
RES: $255.1SUP: $185.0SMA50: $203.7SMA200: $150.7
$234.7$199.3$163.8$128.4$92.90RES $255.1SUP $185.0$200.22026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NUTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ NUTX Butterfly Map β†’ + Track NUTX β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
13.9%/yr Implied 5Y Growth

vs. +82.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NUTX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for NUTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NUTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NUTX)

Consumer Discretionary Rank #6 of 1011 βš”οΈ LQDT vs NUTX Full Matrix β†’

1. Head-to-Head Consumer Discretionary Peer Comparison (NUTX vs. LQDT, RDWR, RSKD, AHG)

Industry: Business Services (90 Tracked Issuers)

Across 1011 tracked Consumer Discretionary securities in the Roarable RQD universe, Nutex Health Inc. (NUTX) ranks #6 by composite RQD confidence (86/100, grade A) and #465 by equity capitalization ($1.44B). Within this direct 5-issuer industry benchmark cohort, NUTX leads on earnings valuation at 20.3x trailing P/E, while NUTX leads on capital efficiency and profitability with 85.0% ROIC and 50.8% gross margin. NUTX currently leads its immediate peer cohort in composite quantitative strength at 86/100 (A).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NUTX ACTIVE
Nutex Health Inc.
A 86/100 20.3x 50.8% 85.0% -4.74% $1.44B Benchmark Subject
LQDT
Liquidity Services Inc.
B 74/100 50.5x 43.8% 12.9% -1.48% $1.42B /lqdt-vs-nutx β†’
RDWR
Radware Ltd.
D+ 58/100 76.5x 80.7% 3.7% -5.62% $1.55B /rdwr-vs-nutx β†’
RSKD
Riskified Ltd. (Class A)
D+ 55/100 β€” 51.7% -20.3% -4.67% $1.22B /rskd-vs-nutx β†’
AHG
Akso Health Group ADS
E 34/100 β€” -0.1% β€” -5.26% $1.14B /ahg-vs-nutx β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001479681

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nutex Health Inc. (NUTX) reported GAAP revenue of $875.3M (+82.4% vs. FY2024 revenue of $479.9M , and +253.4% cumulative change since FY2023) , GAAP net income of $70.8M, operating cash flow of $248.1M, and free cash flow of $245.6M (+1078.0% YoY). On the balance sheet, NUTX closed FY2025 with $918.5M in total assets against $29.2M in total debt (Altman Z-Score: 3.75, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $875.3M $70.8M $248.1M $245.6M $918.5M $29.2M
FY2024 (FY) 2024-12-31 $479.9M $52.1M $23.2M $20.8M $655.3M $22.5M
FY2023 (FY) 2023-12-31 $247.6M -$45.8M $1.3M $1.3M β€” β€”

3. NUTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NUTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Nutex Health Inc. (NASDAQ: NUTX) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 86/100 at a spot price of $200.15 (-4.74% 1D, market cap $1.44B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 19/20. Across 1011 tracked Consumer Discretionary issuers, NUTX ranks #6 in composite RQD confidence.

How does NUTX compare to LQDT and RDWR in the Consumer Discretionary sector?

Within the Consumer Discretionary sector (Business Services), NUTX carries a Roarable A (86/100 RQD), trailing P/E of 20.3x, gross margin of 50.8%, and ROIC of 85.0%. By comparison, LQDT (Liquidity Services Inc.) holds a B grade (74/100 RQD, P/E 50.5x, ROIC 12.9%, cap $1.42B) and RDWR (Radware Ltd.) posts a D+ grade (58/100 RQD, P/E 76.5x, ROIC 3.7%, cap $1.55B). Among the 5-stock peer group, NUTX leads on earnings multiple (20.3x) while NUTX leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NUTX?

Per NUTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001479681), Nutex Health Inc. generated $875.3M in revenue (+82.4% YoY), $70.8M in net income, and $245.6M in free cash flow against $918.5M in total assets and $29.2M in total debt. Key quantitative strengths: Strong cash generator (51% profit margin)β€”profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NUTX trading relative to its 50-day, 200-day, and 52-week technical levels?

NUTX last traded at $200.15 (-4.74% on volume of 120,065 shares), positioning the stock -1.76% below its 50-day simple moving average ($203.73) and +32.84% above its 200-day simple moving average ($150.67). Across its 52-week range of $83.99 to $226.16, NUTX sits at the 81.7% percentile with a 14-day RSI of 53.8 (NEUTRAL RANGE) and an implied next-earnings move of Β±11.2% ($177.73 to $222.57).

NUTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

How profitable is Nutex Health Inc. (NUTX)?

In FY 2025 (10-K), NUTX converted $875.3M of revenue into a 50.8% gross margin, 31.5% operating margin, and $245.6M in free cash flow (28.1% FCF margin).

Direct Sub-Reports: NUTX RQD Cockpit NUTX 12M Forecast NUTX Earnings & Move NUTX Dividends & DRIP NUTX Insiders & 13F NUTX Whale Options NUTX Profit Sankey NUTX News & Why
ROARABLE RATING BRIEF β€’ RQD 86/100 (A) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

NUTX β€” Nutex Health Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:29:13Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NUTX scores 86 out of 100, graded A, with the verdict label "Roarable Strong Buy β€” Excellent Cash & Whale Support." The five pillars are:

  • Fundamental Cash Engine (19/20): The rating cites ROIC of 85% and an FCF yield of 17.07%. For an investor, this is the strongest pillar, indicating high reported returns on invested capital and substantial free cash generation relative to the share price. The FCF yield also implies the market is pricing the stock at a steep discount to its cash output, which is an upside driver if the cash figures persist, though it may reflect skepticism about sustainability.
  • Whale 13F Flow (14/20): The rating references institutional accumulation and options positioning. This is a moderate score; institutional interest is present but less decisive than the fundamental pillars. No holder-level detail is supplied in the source data to verify the magnitude.
  • Insider Conviction (19/20): Per the rating, SEC Form 4 and Congressional PTR cluster flow is strong. High scores here suggest insiders are net-positioned favorably, a conviction signal, though the underlying transaction records are not provided in this dossier.
  • Macro Regime Fit (18/20): The rating cites a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broader market, so it offers neither defensive insulation nor amplified volatility relative to the market.
  • Forensic Balance Sheet (16/20): The rating cites an Altman Z of 3.75, a Piotroski F of 9/9, and Debt/Equity of 0.09. These figures point to low leverage and strong financial-health screens, the lowest-weighted pillar here, which is consistent with a healthy but not flawless balance sheet.

Investor implications: the rating's strength rests mainly on cash-generation metrics and low leverage. The tradeoffs to weigh are that the stock trades at a P/E (TTM) of 20.3 and EV/EBITDA of 4.6, the price sits 1.19% lower on the session, and its 52-week range ($83.99–$226.16) shows wide price dispersion. The RQD is a scoring framework and does not constitute a recommendation.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$210.1$1.44B20.317.14.610.340%1.0$83.99 - $226.1685%

Business

Nutex Health Inc. (NUTX) is a NASDAQ-listed company classified in the Consumer Discretionary sector and Business Services industry, per the profile. Not available in source data for detailed product lines, customer base, or revenue-generation model.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$875.3M$275.6M$70.8MN/A$245.6M$185.6M$29.2M
FY 2024$479.9M$130.7M$52.1MN/A$20.8M$40.6M$22.5M
FY 2023$247.6M$-31.8M$-45.8MN/A$1.3MN/AN/A

Per the SEC financials, revenue rose from $247.6M in FY 2023 to $875.3M in FY 2025, and operating income moved from $-31.8M to $275.6M over the same span. Per the market data, the gross margin is 50.8%, operating margin 31.5%, and net margin 8.1%, with ROIC at 85%. Per the Roarable RQD rating, the Altman Z-Score is 3.75 and the Piotroski F-Score is 9/9. Debt/Equity is 0.09 per the rating. The net margin is notably thinner than the operating margin, which the source data does not explain.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the items are:

  • Motley Fool ("2 Stocks to Buy Hand Over Fist in October"): Market wire, yellow light; a general market-action piece.
  • TradingView (Estimates): Market wire, yellow light; estimates coverage, with no figures given in the source.
  • NAI500 ("These Two Healthcare Stocks Are Beating the Sector, They Still Look Cheap"): Catalyst, green light.
  • Stock Titan: Notes that Nutex Health will discuss its results at 9:30 a.m. Central time on Nov. 6; market wire, yellow light. This is the one dated event in the feed.
  • Simply Wall St ("Could Be 25% Undervalued On Solid Results And Raised Targets"): Catalyst, green light.
  • marketscreener.com (Ladenburg Thalmann initiation): Market wire, yellow light; the headline references a Buy rating and a $336 price target.

Risk watch items: the price target in the Ladenburg headline ($336) is above the 52-week high of $226.16 and above the current price, but this is noted from the headline only and not verified against analyst data. Proprietary signals in the Butterfly graph: none. Supply chain: NONE.

Analyst View & Smart Money Ownership

Analyst data: Not available in source data (analyst_data is NONE). Holder data, including Form 4, 13F, and Congressional trades: Not available in source data (holders is NONE). The Ladenburg Thalmann headline referenced in the news feed states a Buy rating and $336 price target, but this is not corroborated by the analyst data section.

Open Questions

  • Why does net margin (8.1%) sit so far below operating margin (31.5%), and what drives the gap?
  • Is the FY 2025 FCF of $245.6M recurring, given FY 2024 FCF was $20.8M?
  • What do the FY 2025 and FY 2024 EPS figures look like, since both are reported as N/A?
  • Who are the holders and what are the magnitudes of the 13F and insider positions behind the pillar scores?
  • Does the $336 price target in the Ladenburg headline reflect a current, verifiable analyst view?

NUTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nutex Health Inc. (NUTX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to NUTX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NUTX Bull vs. Bear Conversation Board β€” What's Your Call at $200.15?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NUTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NUTX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk πŸ‚ BULLISH 🎯 Target: $247.92 (+18.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is NUTX (A β€’ RQD 86/100) a Buy at $210.10?

Welcome to the NUTX (Nutex Health Inc.) Roar Pit. Current RQD Composite is 86/100 (Roarable Strong Buy β€” Excellent Cash & Whale Support) in Business Services. Bulls point to capital efficiency (85.0% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $157.58 (-25.0%)
Spot @ $210.10

Pump the brakes on NUTX β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NUTX, but look at what you are paying: 20.3x trailing P/E with 50.8% gross margins. Unless Nutex Health Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $247.92 (+18.0%)
Spot @ $210.10

NUTX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NUTX, the market is fixating on short-term headline noise in Business Services and ignoring the balance sheet and cash flow trajectory. At $210.10 (52-wk range $83.99 - $226.16), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%